{"id":751190,"date":"2023-04-26T03:04:01","date_gmt":"2023-04-26T07:04:01","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/"},"modified":"2023-04-26T03:04:01","modified_gmt":"2023-04-26T07:04:01","slug":"mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/","title":{"rendered":"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal"},"content":{"rendered":"

\nThe Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients
\n<\/h2>\n
\n

BERKELEY, Calif. and MAINZ, Germany, April 26, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de Microecologia<\/a> in Madrid to its growing network of lab partners across Europe and in select international markets. ColoAlert\u00ae<\/sup>, Mainz Biomed\u2019s flagship product, is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC). For more than 60 years, the\u00a0Instituto de Microecologia\u00a0has been a pioneer in microbiota studies and food sensitivity, focused on disseminating the importance of intestinal health through microbiological analysis and diagnosis of microbiota profiles and specific health parameters. Entering the market and beginning commercialization in Spain and Portugal signify the continued expansion of Mainz Biomed\u2019s impact in Europe.<\/p>\n

\u201cAs we continue to form partnerships with third-party diagnostic labs such as the\u00a0Instituto de Microecologia for test kit processing, our aim is to increase consumer access to affordable and reliable CRC screening tests like ColoAlert,\u201d said Guido Baechler, Chief Executive Officer of Mainz Biomed. \u201cEarly screening has the potential to dramatically impact the treatment and prevention of this deadly disease, as well as save lives.\u201d<\/p>\n

According to the World Cancer Research Fund International, CRC is the third most common cancer worldwide and Portugal ranks seventh in total global CRC rates with 10,501 cases reported in 2020. On its website, the Institute lists CRC as the second leading cause of death from cancer in Spain and the most frequent malignant tumor, with\u00a041,441 new cases each year affecting\u00a01 in 20 men\u00a0and\u00a01 in 30 women\u00a0before the age of 74. The probability of survival exceeds 90% when detected at an early stage.<\/p>\n

The Instituto de Microecologia is widely known across Spain for its pioneering work in intestinal health. It offers a wide range of diagnostic and analytical services and is continuously advancing its scientific and technical capabilities through ongoing internal research alongside external collaborations. The Institute deploys the most innovative diagnostic techniques by continuously auditing procedures to ensure delivery of the highest standard of quality and reliability of diagnostic results.<\/p>\n

\n About ColoAlert<\/strong>
\n
ColoAlert\u00ae<\/sup>, Mainz Biomed\u2019s flagship product, delivers high sensitivity and specificity in a user-friendly, at-home colorectal cancer (CRC) screening kit. This non-invasive test can be indicative of tumors as determined by analyzing tumor DNA, offering better early detection than fecal occult blood tests (FOBT). Based on PCR-technology, ColoAlert detects more cases of colorectal cancer than other stool tests and allows for an earlier diagnosis (Gies et al., 2018<\/u><\/strong><\/a>). The product is commercially available in select EU countries through a network of leading independent laboratories, corporate health programs and via direct sales. To receive marketing approval in the US, ColoAlert will be evaluated in the FDA-registration trial \u2018ReconAAsense.\u2019 Once approved in the US, the Company\u2019s commercial strategy is to establish scalable distribution through a collaborative partner program with regional and national laboratory service providers across the country.<\/p>\n

\n About Colorectal Cancer<\/strong>
\n
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund International. The US Preventive Services Task Force recommends that screening with stool DNA tests such as ColoAlert should be conducted once every three years starting at age 45. Each year in the US, 16.6 million colonoscopies are performed. However, roughly one-third of US residents aged 50-75 have never been screened for colon cancer. This gap in screening represents a $4.0B+ total market opportunity in the US.<\/p>\n

\n About Mainz Biomed NV<\/strong>
\n
Mainz Biomed develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The Company\u2019s flagship product is ColoAlert, an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. ColoAlert is currently marketed across Europe. The Company is running a pivotal FDA clinical study for US regulatory approval. Mainz Biomed\u2019s product candidate portfolio also includes PancAlert, an early-stage pancreatic cancer screening test. To learn more, visit\u00a0mainzbiomed.com<\/u><\/strong><\/a>\u00a0or follow us on\u00a0LinkedIn<\/u><\/strong><\/a>,\u00a0Twitter<\/u><\/strong><\/a>\u00a0and\u00a0Facebook<\/u><\/strong><\/a>.<\/p>\n

\n For media inquiries, please contact press@mainzbiomed.com<\/strong>\n <\/p>\n

In Europe:
MC Services AG
Anne Hennecke\/Caroline Bergmann
+49 211 529252 20
mainzbiomed@mc-services.eu<\/p>\n

In the US:
Spectrum Science
Melissa Laverty\/Valerie Enes
+1 540 272 6465
mainz@spectrumscience.com<\/p>\n

\n For investor inquiries, please contact info@mainzbiomed.com<\/strong>\n <\/p>\n

\n Forward-Looking Statements<\/strong>
\n
Certain statements made in this press release are \u201cforward-looking statements\u201d within the meaning of the \u201csafe harbor\u201d provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cestimate\u201d, \u201cplan\u201d, \u201coutlook\u201d, and \u201cproject\u201d and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements reflect the current analysis of existing information and are subject to various risks and uncertainties. As a result, caution must be exercised in relying on forward-looking statements. Due to known and unknown risks, actual results may differ materially from the Company\u2019s expectations or projections. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: (i) the failure to meet projected development and related targets; (ii) changes in applicable laws or regulations; (iii) the effect of the COVID-19 pandemic on the Company and its current or intended markets; and (iv) other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the Securities and Exchange Commission (the \u201cSEC\u201d) by the Company. Additional information concerning these and other factors that may impact the Company\u2019s expectations and projections can be found in its initial filings with the SEC, including its annual report on Form 20-F filed on May 5, 2022. The Company\u2019s SEC filings are available publicly on the SEC\u2019s website at www.sec.gov. Any forward-looking statement made by us in this press release is based only on information currently available to Mainz Biomed and speaks only as of the date on which it is made. Mainz Biomed undertakes no obligation to publicly. update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise, except as required by law.<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients BERKELEY, Calif. and MAINZ, Germany, April 26, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets. ColoAlert\u00ae, Mainz Biomed\u2019s flagship product, is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC). For more than 60 years, the\u00a0Instituto de Microecologia\u00a0has been a pioneer in microbiota studies and food sensitivity, focused on disseminating the importance of intestinal health through microbiological analysis … <\/p>\n

Continue reading “Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-751190","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nMainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients BERKELEY, Calif. and MAINZ, Germany, April 26, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets. ColoAlert\u00ae, Mainz Biomed\u2019s flagship product, is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC). For more than 60 years, the\u00a0Instituto de Microecologia\u00a0has been a pioneer in microbiota studies and food sensitivity, focused on disseminating the importance of intestinal health through microbiological analysis … Continue reading "Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-26T07:04:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal\",\"datePublished\":\"2023-04-26T07:04:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/\"},\"wordCount\":1074,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/\",\"name\":\"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==\",\"datePublished\":\"2023-04-26T07:04:01+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/","og_locale":"en_US","og_type":"article","og_title":"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal - Market Newsdesk","og_description":"The Instituto de Microecologia to market at-home detection test for colorectal cancer to physicians and their patients BERKELEY, Calif. and MAINZ, Germany, April 26, 2023 (GLOBE NEWSWIRE) — Mainz Biomed NV (NASDAQ:MYNZ) (\u201cMainz Biomed\u201d or the \u201cCompany\u201d), a molecular genetics diagnostic company specializing in the early detection of cancer, announced that it has added the Instituto de Microecologia in Madrid to its growing network of lab partners across Europe and in select international markets. ColoAlert\u00ae, Mainz Biomed\u2019s flagship product, is a highly efficacious and easy-to-use, at-home detection test for colorectal cancer (CRC). For more than 60 years, the\u00a0Instituto de Microecologia\u00a0has been a pioneer in microbiota studies and food sensitivity, focused on disseminating the importance of intestinal health through microbiological analysis … Continue reading \"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/","og_site_name":"Market Newsdesk","article_published_time":"2023-04-26T07:04:01+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal","datePublished":"2023-04-26T07:04:01+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/"},"wordCount":1074,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/","name":"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==","datePublished":"2023-04-26T07:04:01+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=MTAwMDgwNjA2MyM0MDE1MzE4NTQjMjIyNDA4OQ=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mainz-biomed-announces-partnership-with-the-instituto-de-microecologia-to-expand-coloalert-commercialization-in-spain-and-portugal\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mainz Biomed Announces Partnership with the Instituto de Microecologia to Expand ColoAlert\u00ae Commercialization in Spain and Portugal"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751190","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=751190"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/751190\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=751190"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=751190"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=751190"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}